Medical device maker Dexcom said the use of its continuous glucose monitor, G7, led to improved blood sugar control in ...
DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of ...
DexCom, Inc. (NASDAQ:DXCM) will present new clinical findings, product advancements and strategic business initiatives ...
A new study presented at the American Diabetes Association found that Dexcom’s G7 continuous glucose monitor significantly ...
People with diabetes who use the Dexcom G7 continuous glucose monitoring system need to check the lot numbers on sensors. Dexcom reported on May 26, 2026, that through internal reviews it had ...
The FDA has officially cleared the Dexcom G5 continuous glucose monitor to inform treatment decisions -- without the use of a fingerstick glucometer, other than for calibration. The G5 has been ...
If you have either of these, throw them out ASAP.
The diabetes tech firm has identified two lots of G7 sensors that have been stolen, sold and used by customers.
MADRID--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the leader in continuous glucose monitoring (CGM), announced today the Dexcom G6 CGM System has received the CE Mark for use during pregnancy in ...
Dexcom says stolen G7 sensors from two scrapped lots were sold through unauthorized channels, creating infection and reading-failure risks.
DexCom says certain lots of Dexcom G7 sensors originally designated as scrap and intended for destruction were stolen during the destruction process, then sold by third parties.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results